Targeting hypoxia tolerance in cancer.

Regulation of tissue oxygen homeostasis is critical for cell function, proliferation and survival. Evidence for this continues to accumulate along with our understanding of the complex oxygen-sensing pathways present within cells. Several pathophysiological disorders are associated with a loss in oxygen homeostasis, including heart disease, stroke, and cancer. The microenvironment of tumors in particular is very oxygen heterogeneous, which may explain much of our difficulty in treating cancer effectively. This is true when comparing levels of hypoxia among different patient tumors, but also within individual tumors. Accumulating evidence implicates the biological responses to hypoxia and the alterations in these pathways in cancer as important contributors to overall malignancy and treatment efficacy. This has recently prompted several investigations into the possibility of targeting treatment at the biological responses to hypoxia.

[1]  T Kobayashi,et al.  Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. , 2001, Genes & development.

[2]  M. Gassmann,et al.  Defective Brain Development in Mice Lacking the Hif-1α Gene in Neural Cells , 2003, Molecular and Cellular Biology.

[3]  Erwin G. Van Meir,et al.  Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells , 2000, The Journal of experimental medicine.

[4]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[5]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[6]  T. Danielsen,et al.  Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis , 1999, British Journal of Cancer.

[7]  M. Hentze,et al.  From factors to mechanisms: translation and translational control in eukaryotes. , 1999, Current opinion in genetics & development.

[8]  Dihua Yu,et al.  Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone , 2003, Cancer.

[9]  A. Giaccia,et al.  Hypoxic Stress Proteins: Survival of the Fittest. , 1996, Seminars in radiation oncology.

[10]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[11]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[12]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[13]  J. Nemunaitis,et al.  Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  P. Sarnow,et al.  Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites. , 1998, RNA.

[15]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. , 2000, Cancer research.

[16]  M. Gassmann,et al.  Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. , 1998, Cancer research.

[17]  W. Oyen,et al.  Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Hustin,et al.  Maternal circulation in the first-trimester human placenta--myth or reality? , 1997, American journal of obstetrics and gynecology.

[19]  H. Suzuki,et al.  An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. , 1998, Hybridoma.

[20]  P. Buc-Calderon,et al.  Adenine nucleotides and inhibition of protein synthesis in isolated hepatocytes incubated under different pO2 levels. , 1993, Archives of biochemistry and biophysics.

[21]  A. Giaccia,et al.  Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  V. Gekeler,et al.  Replicon initiation frequency and intracellular levels of ATP, ADP, AMP and of diadenosine 5',5'''-P1,P4-tetraphosphate in ehrlich ascites cells cultured aerobically and anaerobically. , 1983, Biochemical and biophysical research communications.

[23]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[24]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[25]  C. Meares,et al.  Molecular tools for targeted imaging and therapy of cancer , 2003, Journal of molecular recognition : JMR.

[26]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[27]  D. Kirkpatrick,et al.  The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. , 2003, Molecular cancer therapeutics.

[28]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .

[29]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[30]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[31]  H. Hurwitz,et al.  Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. , 2003, Seminars in oncology.

[32]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[33]  N. Tamaki,et al.  Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. , 2003, The American journal of pathology.

[34]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[35]  Edward S. Kim,et al.  IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer , 2001, Seminars in oncology.

[36]  Johan Bussink,et al.  Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  Erwin G. Van Meir,et al.  Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. , 2002, Cancer research.

[38]  W. Heiss,et al.  Molecular Imaging of Gliomas , 2002, Molecular imaging.

[39]  Jianzhong Huang,et al.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[41]  P. Workman.  Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.

[42]  J. Pastorek,et al.  Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion , 2000, British Journal of Cancer.

[43]  A. Sica,et al.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter , 1995, The Journal of experimental medicine.

[44]  A. Fornace,et al.  Regulation of translation initiation following stress , 1999, Oncogene.

[45]  P Lambin,et al.  Hypoxia as a target for combined modality treatments. , 2002, European journal of cancer.

[46]  V. Gekeler,et al.  Oxygen dependent regulation of DNA synthesis and growth of Ehrlich ascites tumor cells in vitro and in vivo. , 1988, Cancer research.

[47]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[48]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[49]  M. Imamura,et al.  Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  Brett L Carlson,et al.  Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.

[51]  A. Burny,et al.  Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. , 1999, European Respiratory Journal.

[52]  J. Sandvik,et al.  Regulation of protein synthesis in human cells exposed to extreme hypoxia. , 1995, Anticancer research.

[53]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[54]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[55]  Sutherland,et al.  Tumor Hypoxia and Heterogeneity: Challenges and Opportunities for the Future. , 1996, Seminars in radiation oncology.

[56]  M. Clemens,et al.  Translational control: the cancer connection. , 1999, The international journal of biochemistry & cell biology.

[57]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[58]  G. Semenza,et al.  Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. , 1999, Developmental biology.

[59]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[60]  E. Pettersen,et al.  Regulation of protein metabolism of human cells during and after acute hypoxia. , 1986, Cancer research.

[61]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[62]  R. Sutherland,et al.  Resistance to adriamycin in multicellular spheroids. , 1979, International journal of radiation oncology, biology, physics.

[63]  S. Hill,et al.  Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. , 1995, British Journal of Cancer.

[64]  A. Komar,et al.  The Zipper Model of Translational Control A Small Upstream ORF Is the Switch that Controls Structural Remodeling of an mRNA Leader , 2003, Cell.

[65]  Cherrington,et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.

[66]  P. Thibault,et al.  Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells , 2001, Molecular and Cellular Biology.

[67]  Tarik Tihan,et al.  The hypoxic response of tumors is dependent on their microenvironment. , 2003, Cancer cell.

[68]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[69]  J. Price.  The biology of metastatic breast cancer , 1990, Cancer.

[70]  A. Harris,et al.  Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.

[71]  J. Waldrep,et al.  Camptothecins and lung cancer: improved delivery systems by aerosol. , 2003, Current cancer drug targets.

[72]  A. Berns,et al.  Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice , 2001, Nature.

[73]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[74]  P. Lambin,et al.  Modulation of cell death in the tumor microenvironment. , 2003, Seminars in radiation oncology.

[75]  J. McCubrey,et al.  BAY-43-9006 Bayer/Onyx. , 2003, Current opinion in investigational drugs.

[76]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[77]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[78]  P. Fisher,et al.  Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. , 2003, Seminars in cancer biology.

[79]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[80]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[81]  P. Brown,et al.  Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[82]  A. Giaccia,et al.  ATR/ATM Targets Are Phosphorylated by ATR in Response to Hypoxia and ATM in Response to Reoxygenation* , 2003, The Journal of Biological Chemistry.

[83]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[84]  M. Tsao,et al.  Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. , 1992, Oncogene.

[85]  W. Sly,et al.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.

[86]  S. Dower,et al.  Response of tumour cells to hypoxia: role of p53 and NFkB. , 1998, Molecular pathology : MP.

[87]  P. Pandolfi,et al.  Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.

[88]  P. Sarnow,et al.  Internal ribosome entry sites in eukaryotic mRNA molecules. , 2001, Genes & development.

[89]  C. Frelin,et al.  Differential regulation of cardiac heme oxygenase‐1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia , 1996, FEBS letters.

[90]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[91]  M. Goldberg,et al.  Regulation of the erythropoietin gene , 1993, Blood.

[92]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[93]  R. Bruick,et al.  Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. , 2003, Genes & development.

[94]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[95]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[96]  N. Senzer,et al.  Enhanced oncolytic potency of replicative adenovirus expressing p53. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[97]  G. Goodall,et al.  Hypoxia-inducible Factor-1 (cid:1) mRNA Contains an Internal Ribosome Entry Site That Allows Efficient Translation during Normoxia and Hypoxia , 2022 .

[98]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[99]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[100]  M. Kozak.  Initiation of translation in prokaryotes and eukaryotes. , 1999, Gene.

[101]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[102]  T. E. Dever,et al.  Translation initiation: adept at adapting. , 1999, Trends in biochemical sciences.

[103]  L. Grochow,et al.  Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors , 2001, Cancer Chemotherapy and Pharmacology.

[104]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[105]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[106]  B. Ebert,et al.  Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[107]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[108]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[109]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Pastorek,et al.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.

[111]  O. S. Nielsen,et al.  Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations , 2001, British Journal of Cancer.

[112]  Zhong Yun,et al.  Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. , 2002, Developmental cell.

[113]  W. Sivitz,et al.  Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. , 1992, The American journal of physiology.

[114]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[115]  L. Neckers,et al.  Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway* , 2002, The Journal of Biological Chemistry.

[116]  T. Graeber,et al.  Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. , 1997, Cancer research.

[117]  M. Gassmann,et al.  Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ3 , 2000 .

[118]  J. Nortier,et al.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  E. Leung,et al.  Regression of solid tumors by engineered overexpression of von Hippel–Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1α , 2003, Gene Therapy.

[120]  G. Krause,et al.  Suppression of protein synthesis in brain during hibernation involves inhibition of protein initiation and elongation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[121]  Sophie Bonnal,et al.  IRESdb: the Internal Ribosome Entry Site database , 2003, Nucleic Acids Res..

[122]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[123]  P. Vaupel,et al.  Oxygenation of human tumors: the Mainz experience. , 1998, Strahlentherapie und Onkologie (Print).

[124]  J. Pastorek,et al.  Expression of MaTu‐MN protein in human tumor cultures and in clinical specimens , 1993, International journal of cancer.

[125]  S. Dai,et al.  Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. , 2003, International journal of radiation oncology, biology, physics.

[126]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[127]  W. Friedrichs,et al.  Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[128]  A. Giaccia,et al.  Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. , 1999, Cancer research.

[129]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[130]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[131]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[132]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[133]  G. Semenza,et al.  Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. , 1999, Cancer research.

[134]  J. Simons,et al.  2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. , 2003, Cancer cell.

[135]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[136]  N. Sonenberg,et al.  The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts , 1992, Molecular and cellular biology.

[137]  R. Sutherland,et al.  Influence of growth phase, nutrition and hypoxia on heterogeneity of cellular buoyant densities in in vitro tumor model systems , 1986, International journal of cancer.

[138]  N. Socci,et al.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.

[139]  J. Mestan,et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.

[140]  A. Harris,et al.  Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. , 2003, Cancer research.

[141]  P. Vaupel,et al.  Predictive power of the tumor oxygenation status. , 1999, Advances in experimental medicine and biology.

[142]  R. Herbst,et al.  IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. , 2002, Expert opinion on biological therapy.

[143]  N. Sonenberg,et al.  Abrogation of translation initiation factor eIF‐2 phosphorylation causes malignant transformation of NIH 3T3 cells. , 1995, The EMBO journal.

[144]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[145]  A. Harris,et al.  Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. , 2000, Cancer research.

[146]  H. Riedinger,et al.  Fast Control of DNA Replication in Response to Hypoxia and to Inhibited Protein Synthesis in CCRF-CEM and HeLa Cells , 1999, Biological chemistry.

[147]  A. Giaccia,et al.  Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.

[148]  N. Usman,et al.  Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. , 2000, The Journal of clinical investigation.

[149]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[150]  E. Leung,et al.  Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy , 2001, Gene Therapy.

[151]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[152]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[153]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[154]  A. Giaccia,et al.  Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. , 1998, The cancer journal from Scientific American.

[155]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[156]  P. Einat,et al.  Translation of Vascular Endothelial Growth Factor mRNA by Internal Ribosome Entry: Implications for Translation under Hypoxia , 1998, Molecular and Cellular Biology.

[157]  N. Sonenberg,et al.  Regulation of Protein Synthesis by Hypoxia via Activation of the Endoplasmic Reticulum Kinase PERK and Phosphorylation of the Translation Initiation Factor eIF2α , 2002, Molecular and Cellular Biology.

[158]  A. Giaccia,et al.  Hypoxia Links ATR and p53 through Replication Arrest , 2002, Molecular and Cellular Biology.

[159]  Yoon Ki Kim,et al.  Continuous heat shock enhances translational initiation directed by internal ribosomal entry site. , 2002, Biochemical and biophysical research communications.

[160]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[161]  T. Graeber,et al.  Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status , 1994, Molecular and cellular biology.

[162]  J. Freyer,et al.  Cellular growth and metabolic adaptations to nutrient stress environments in tumor microregions. , 1986, International journal of radiation oncology, biology, physics.

[163]  T. Resink,et al.  Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[164]  T. Fojo.  p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[165]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[166]  C. N. Coleman,et al.  Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!). , 2003, Radiology.

[167]  C. Koch.  Oxygen effects in radiobiology. , 1982, Advances in experimental medicine and biology.

[168]  P. Disaia,et al.  Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. , 1994, The American journal of pathology.

[169]  M. Asaka,et al.  Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. , 2001, Cancer research.

[170]  W. Figg,et al.  2‐Methoxyestradiol, a Promising Anticancer Agent , 2003, Pharmacotherapy.